Skip to main content
editorial
. 2015 Aug 10;6(9):1092–1096. doi: 10.4239/wjd.v6.i9.1092

Figure 2.

Figure 2

Selected outcome trials in type 2 diabetes with a focus on di-peptidyl peptidase-4 inhibitor studies, and their results, in the context of the duration of intervention and the study population’s diabetes duration and baseline cardiovascular risk. CV: Cardiovascular; UKPDS: United Kingdom Prospective Diabetes Study; VADT: Veterans affairs diabetes trial.